Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2).
Volker Moebus
Honoraria - Amgen; GlaxoSmithKline; Pfizer; Roche; Sanofi
Research Funding - Amgen; Johnson & Johnson; Novartis; Roche
Helmut Forstbauer
No relevant relationships to disclose
Grischa Wachsmann
No relevant relationships to disclose
Andreas Schneeweiss
Consultant or Advisory Role - Celgene; Roche
Honoraria - Celgene; Roche
Research Funding - Celgene
Expert Testimony - Roche
Angelika Ober
No relevant relationships to disclose
Ekkehard von Abel
No relevant relationships to disclose
Petra Krabisch
No relevant relationships to disclose
Heinz-Gert Hoeffkes
No relevant relationships to disclose
Karin Kast
No relevant relationships to disclose
Bernd Christensen
No relevant relationships to disclose
Michael Niedermeier
No relevant relationships to disclose
Mustafa Deryal
No relevant relationships to disclose
Christoph Uleer
No relevant relationships to disclose
Yvonne Fauster
No relevant relationships to disclose
Thomas Goehler
No relevant relationships to disclose
Sibylle Loibl
Honoraria - Celgene; Roche
Valentina Nekljudova
No relevant relationships to disclose
Gunter Von Minckwitz
Honoraria - Amgen; Celgene; Roche
Research Funding - Amgen; Celgene; Roche